Format
Sort by

Send to

Choose Destination

Search results

Items: 5

1.

Cost-effectiveness analysis of palivizumab as respiratory syncytial virus prophylaxis in preterm infants in Sweden.

Neovius K, Buesch K, Sandström K, Neovius M.

Acta Paediatr. 2011 Oct;100(10):1306-14. doi: 10.1111/j.1651-2227.2011.02309.x. Epub 2011 May 13.

PMID:
21477089
2.

Comment and reply on: The cost-effectiveness of palivizumab for respiratory syncytial virus prophylaxis in premature infants with a gestational age of 32-35 weeks: a Canadian-based analysis.

Robinson JL.

Curr Med Res Opin. 2009 Jul;25(7):1631-2; author reply 1632-3. doi: 10.1185/03007990902993415. No abstract available.

PMID:
19480611
3.

The cost-effectiveness of palivizumab for respiratory syncytial virus prophylaxis in premature infants with a gestational age of 32-35 weeks: a Canadian-based analysis .

Lanctôt KL, Masoud ST, Paes BA, Tarride JE, Chiu A, Hui C, Francis PL, Oh PI.

Curr Med Res Opin. 2008 Nov;24(11):3223-37. doi: 10.1185/03007990802484234 . Epub 2008 Oct 16.

PMID:
18928643
4.

Cost effectiveness of palivizumab for respiratory syncytial virus prophylaxis in high-risk children: a UK analysis.

Nuijten MJ, Wittenberg W, Lebmeier M.

Pharmacoeconomics. 2007;25(1):55-71.

PMID:
17192118
5.

Palivizumab for respiratory syncytial virus prophylaxis in high-risk infants: a cost-effectiveness analysis.

Lofland JH, O'Connor JP, Chatterton ML, Moxey ED, Paddock LE, Nash DB, Desai SA.

Clin Ther. 2000 Nov;22(11):1357-69.

PMID:
11117660

Supplemental Content

Loading ...
Support Center